Cotrisan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cotrisan

Quick Facts

Property Description
Active Ingredient Clotrimazole (INN)
Pharmacological Class Azole Antifungal Agent
Forms (Localized) Cream, Solution, Tablet/Suppository
General Purpose To inhibit fungal growth
Origin Synthetic Compound

As a preparation containing the active ingredient Clotrimazole, Cotrisan is fundamentally a medication classified as an Antifungal agent, designed to address imbalances caused by susceptible fungal overgrowth. Its identity is defined by its selective action as an Antimycotic medicine.


What Pharmacological Class Does Cotrisan Belong To?

Cotrisan belongs to the Azole antifungal class of medicines, which are characterized by their ability to specifically target and disrupt the essential functions of fungal cells. This pharmacological classification means the drug's core therapeutic purpose is to manage conditions where fungal proliferation is the underlying issue. The active compound, Clotrimazole, is clinically recognized as a broad-spectrum antifungal, effective against a variety of pathogenic fungal organisms. This indicates that the medicine has established utility in managing surface fungal overgrowth. Clotrimazole formulations are often recommended by pharmacists for localized dermatological issues, a common scenario for this class of medicine.


Composition and Origin: Is Clotrimazole a Synthetic Compound?

The active ingredient in Cotrisan is Clotrimazole (INN), a pure synthetic compound that is chemically recognized as an Imidazole derivative. Cotrisan is typically manufactured as a single-agent product, with its therapeutic benefits derived solely from the Clotrimazole molecule. The composition includes this active ingredient combined with an inert Base/Vehicle, such as a cream emulsion, solution vehicle, or solid excipients, which are necessary to safely deliver the medication to the site of application. Widely recognized global brands like Lotrimin and Canesten utilize this exact active ingredient and mechanism, demonstrating its established status in the medical field.


Types of Cotrisan: Understanding Dosage Forms and Administration

Cotrisan is a preparation specifically formulated for localized delivery to maximize its concentration at the site of need. The product is designed for its use as a localized treatment. The product is available in several Dosage forms, including a Cream or Solution for skin application, and specialized forms such as Vaginal Suppositories/Tablets or Oral Lozenges (Troches). These various types dictate the appropriate Route of administration, which is strictly localized, encompassing Topical, Intravaginal, and Oropharyngeal routes, depending on the specific formulation.

Regulatory References

  1. Clotrimazole - StatPearls - NCBI Bookshelf

What side effects are possible with Cotrisan?

Possible Side Effects and Safety Information

Regulatory documentation for the active ingredient, Clotrimazole, classifies adverse reactions according to established frequency categories and System-Organ Classes (SOCs). The safety profile is largely defined by localized reactions, which are the most common reported events.


Documented Adverse Reactions

The most frequently observed adverse reactions at the site of administration (skin or mucosa) are classified as Common. These include local irritation, a burning or stinging sensation, erythema (redness), and pruritus (itching). Reactions specific to intravaginal use may include vulvovaginal discomfort, pain, and discharge.

For many post-marketing events, including rare systemic reactions, the frequency is classified as Frequency Not Known by regulatory authorities. These documented events relate to various System-Organ Classes, including Skin and Subcutaneous Tissue Disorders, Reproductive System and Breast Disorders, and Immune System Disorders.

Serious Safety Considerations

Official labeling records rare, clinically significant systemic reactions that are typically manifestations of a generalized allergic response. These Serious Adverse Reactions include events such as anaphylactic reaction, angioedema, syncope (fainting), and hypotension (low blood pressure).

Specific Safety Notes

Safety documents list specific constraints regarding use. For the intravaginal formulation, there is a restriction noting that the product may damage latex contraceptives (condoms and diaphragms), potentially reducing their effectiveness. Use of the medication is contraindicated in individuals with known hypersensitivity to the active substance or any of the formulation's excipients. Furthermore, official notes advise that use during the first trimester of pregnancy should occur only if considered essential.

Overdose and Emergency Response

The official regulatory profile for Cotrisan (Clotrimazole) overdose is primarily defined by the minimal systemic absorption of the active ingredient following its intended localized application. Due to this characteristic, the risk of acute intoxication is not expected after a single dermal application over a large area, nor is it anticipated following the inadvertent oral ingestion of localized formulations. Acute overdosage resulting from topical administration is classified in prescribing information as unlikely to cause a life-threatening situation.

The official guidance mandates a clear emergency response for one specific scenario: accidental oral ingestion. In the event this occurs, urgent medical attention is required, and individuals must immediately contact a Poison Control Center or local emergency services. This action applies to all populations, with specific regulatory notes regarding children less than 12 years of age in the context of accidental ingestion of certain dosage forms.

In the management of documented overdose situations, no specific antidote is known. Therefore, the established approach is limited to general symptomatic and supportive measures. Management procedures, such as gastric lavage, are rarely required and are reserved for circumstances where a life-threatening amount was ingested or when clinical symptoms, such as dizziness, nausea, or vomiting, become apparent.

Therapeutic Uses of Cotrisan

What Cotrisan Treats: Main Uses and Benefits

Cotrisan is a specialized antifungal agent focused on providing symptomatic relief and support across distinct areas of localized fungal and yeast overgrowth. It is applied in contexts where short-term symptomatic assistance is needed to ease discomfort and help manage infectious manifestations. Clotrimazole is used to treat a wide range of common fungal infections.


Relief from Common Skin Fungal Infections

This therapeutic domain encompasses infections of the outer skin, such as athlete’s foot, jock itch, and ringworm. Cotrisan is relevant for easing symptoms that may become intense or disruptive, including intense itching, burning, redness, and the disruptive patterns of scaling and cracking. It is commonly used across conditions characterized by periods of heightened symptoms, helping to improve day-to-day comfort during these periods.

Management of Cutaneous and Mucosal Yeast Discomfort

This area focuses on symptoms driven by Candida yeast overgrowth affecting skin folds or mucosal tissues, including oral thrush and vulvovaginal candidiasis. Cotrisan is relevant in clinical settings marked by increased discomfort, as it supports patients during episodes of heightened discomfort by easing distress and irritation associated with yeast proliferation, providing support that contributes to easing the overall symptom load.

Supportive Use in Specific Clinical Scenarios

Cotrisan is also applied in situations requiring supportive symptom management, such as addressing secondary fungal nappy rash or as a targeted measure for managing the incidence of symptomatic episodes of oral thrush in certain high-risk individuals. It helps maintain a sense of stability when localized symptoms are more noticeable, aligning with domains where supportive relief for specific symptomatic episodes is appropriate.


Key Focus: Symptom Domains

Symptom Focus Conditions Addressed Primary Benefit
Itching and Burning Tinea, Vulvovaginal Candidiasis Contributes to easing distress
Scaling and Redness Dermatophyte Infections Contributes to comfort
Soreness and Irritation Mucosal Yeast Infections Assists with functional stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The drug product Cotrisan is not an officially recognized designation in major regulatory databases. This eligibility profile is based on the components Clotrimazole and Betamethasone Dipropionate, a combination found in authorized topical medications.

Eligibility Map: Who can and cannot use [Clotrimazole and Betamethasone Dipropionate Cream] — official regulatory information

Scope Regulatory Status
Populations for whom use is contraindicated: Patients with a known hypersensitivity to clotrimazole, betamethasone, other corticosteroids, or any other ingredient in the formulation. Contraindicated for use with untreated bacterial, tubercular, and certain viral infections of the skin (e.g., herpes simplex, chicken pox).
Age-related eligibility rules: Use is not recommended for patients under the age of 17 years (FDA-stated rule) due to a greater susceptibility to systemic absorption and the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression.
Pregnancy and lactation eligibility status: Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. Avoid extensive use or prolonged periods. Lactation/Nursing Mothers: Caution should be exercised as it is not known if the drug is excreted in human milk.
Eligibility-related restrictions: External use only; not for ophthalmic, oral, or intravaginal use. The medicine is not recommended for diaper dermatitis or for use under occlusive dressings (bandages/coverings).

What should I know about interactions with other medicines?

The official regulatory profile for Cotrisan (Clotrimazole) defines interaction constraints based on the product’s local effects and its metabolic pathway influence.


Interaction Scope

Category Entity/Statement
Medicinal products with documented interactions Oral Immunosuppressants (Tacrolimus, Sirolimus), Other Topical Antifungal Agents.
Mechanistic basis of interactions Pharmacodynamic (physical effect on localized materials); Pharmacokinetic (CYP3A4 inhibition leading to increased systemic exposure of co-administered drugs).
Timing-based interaction rules Alternative barrier precautions must be used for at least five days following vaginal treatment when relying on latex contraceptives.

Official Interaction Statements

  • Co-administration of the vaginal formulation with oral Tacrolimus or Sirolimus might lead to increased plasma concentrations of these immunosuppressants. This is related to Clotrimazole's documented potential as a CYP3A4 inhibitor.
  • Vaginal formulations may damage latex barrier contraceptives (condoms and diaphragms), which could result in a reduction in their effectiveness. This restriction applies to the duration of treatment and the period immediately following.
  • Tampons, douches, spermicides, or other vaginal products must not be used during the course of treatment with vaginal formulations.
  • Co-administration may reduce the antifungal effect of other topical agents, specifically certain polyene antibiotics.
  • Patients with hepatic impairment require periodic monitoring of liver function tests when using the systemically absorbed oral lozenge formulation, a specific interaction-related consideration.

Mechanism of Action

Cotrisan (Clotrimazole) exerts its action by selectively targeting the ergosterol biosynthesis pathway within susceptible fungal cells. The molecule functions as an inhibitor of the enzyme lanosterol 14-alpha-demethylase (14alpha DM), which is a key component of the fungal cytochrome P450 system.

Inhibition of 14alpha DM creates a two-fold mechanistic cascade: it blocks the necessary synthesis of ergosterol, while simultaneously causing the accumulation and incorporation of toxic 14-methyl sterols into the fungal membrane. This structural compromise results in a profound increase in membrane permeability, which disrupts cellular homeostasis by causing the uncontrolled leakage of essential intracellular substances (such as ions and amino acids). This physiological process culminates in the severe impairment of fungal proliferation and viability. The mechanism is constrained when fungal organisms develop resistance through mutations or overexpression of the 14alpha DM target enzyme.

Dosage and Administration Information

Cotrisan (Clotrimazole) is utilized according to standards that define its administration route, dosing schedule, and required procedural steps. As a localized antifungal, the medicine is indicated for delivery via three routes: Topical (dermal), Intravaginal, and Oropharyngeal (oral/buccal), which correspond to specific formulations such as creams, solutions, suppositories, and 10 mg lozenges.


Administration frequency depends strictly on the route and regimen. The topical cream or solution is generally applied twice daily to the affected area. Intravaginal formulations (suppositories or creams) are typically administered once daily, often inserted at bedtime to ensure retention. For oropharyngeal use, the lozenge is administered multiple times a day (three to five times depending on the regimen) and must be allowed to dissolve slowly in the mouth without being chewed or swallowed.


A central rule of use is the completion of the full course, which is specified in product labeling, regardless of symptom resolution. Topical regimens range from 2 to 4 weeks, while vaginal treatments range from 1 to 7 consecutive days, based on the dose strength. Standard instructions also stipulate that the lozenge must be dissolved over approximately 30 minutes, and the topical preparation must avoid contact with the eyes. Pediatric use is generally limited by specific age cutoffs for each route of administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Cotrisan

Evidence for Common Localized Fungal Infections

The research exploring Cotrisan (Clotrimazole) for common localized fungal skin infections (such as tinea) and vulvovaginal candidiasis primarily involves Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies primarily monitor mycological outcomes (status of fungal detectability) and clinical outcomes (changes in patient-reported discomfort and visible signs).

Findings describe patterns observed in the studies, documenting that the medicine's use was associated with measured shifts in both mycological and clinical measures during the observation period. For uncomplicated vaginal yeast infections, research has explored whether short-course treatment regimens showed patterns related to mycological eradication. However, evidence quality varies across studies, and the results apply only to the populations studied.

Research in Specialized and High-Risk Contexts

The use of Cotrisan for oropharyngeal candidiasis (thrush) was studied in controlled clinical trials, often by comparing outcomes with other active medicines instead of a placebo. Research populations included children over three years old and a focus on medically high-risk groups, such as immunocompromised patients. Studies also monitored use in symptomatic pregnant women for vulvovaginal candidiasis. Generalizability is limited, as most evidence is concentrated on high-risk groups.

Evidence Gaps and Areas of Uncertainty

Clinical trials for Cotrisan primarily focus on short-term symptom patterns, meaning follow-up durations were typically limited. Long-term effects are not fully established regarding sustained outcomes after treatment discontinuation. Data for certain groups, such as those with specific non-albicans fungal species or rare comorbidities, remain insufficient. Research provides context but not individual predictions.

Key Studies & References

  1. Clotrimazole Topical (Cream, Solution) Drug Information
  2. Clotrimazole Troche (Lozenges) Official FDA-Approved Labeling and Monograph

Frequently Asked Questions (FAQ)

Common questions about Cotrisan (FAQ)


Q: What is the main difference between Cotrisan and the other similar medication mentioned in commercials?

A: Official information describes how the active ingredient in Cotrisan works by interfering with the synthesis of the fungal cell membrane. This specific mechanism helps block the necessary formation of essential membrane components. This action may differ from certain other antifungal agents that function by compromising the membrane through a different physical or chemical process.

Q: Can Cotrisan make you feel tired or drowsy?

A: Drowsiness is not listed among the most commonly observed side effects for this medication. However, official safety documents have recorded drowsiness as a rare event that may be associated with a serious, generalized allergic reaction.

Q: How long does it usually take to notice an effect from Cotrisan?

A: For certain skin infections, regulatory guidance suggests that a measurable shift in symptoms is expected within two to four weeks, depending on the site being treated. For vaginal infections, a positive change in therapeutic response is generally observed after one week of use.

Q: Does Cotrisan have a 'ceiling' effect where taking more doesn't help?

A: Regulatory documents define specific dosage amounts and frequencies for each route of administration based on established pharmacological testing. These amounts are established as the maximum tested levels in regulatory documents.

Q: Why do official documents say Cotrisan is used for [condition X] but people also talk about [related condition Y]?

A: Official documents classify the approved therapeutic uses for the active ingredient, and these may vary depending on the specific dosage form and concentration (such as a topical cream versus an oral lozenge). The various approved formulations allow the medicine to be used for different localized fungal infections.

Q: How long does Cotrisan stay in your system after you stop taking it?

A: The amount of the active ingredient that is absorbed into the bloodstream is very small due to its localized use. This small systemic fraction has an elimination half-life of approximately two hours, which is the timeframe used to measure its elimination from the body. The remainder of the medicine is largely metabolized by the liver and excreted through bile.

Q: Can you drive or operate machinery while taking Cotrisan?

A: Official documents do not include a standard, general warning against driving or operating machinery while using this medicine. However, they list side effects such as dizziness or fainting (syncope) as rare, serious adverse events that could potentially impact concentration and motor skills.

Q: Can Cotrisan interact with herbal supplements like St. John's Wort?

A: The active ingredient has the potential to affect certain liver enzymes, but the medicine’s localized application routes result in limited systemic absorption. Official data focuses on the limited systemic absorption, which is a key factor in assessing systemic interaction risk.

Q: How do doctors monitor the effectiveness of Cotrisan?

A: Effectiveness is generally monitored by observing the patient's physical symptoms and the healing of the affected skin or mucosal lesions throughout the full course of treatment. Official guidelines often state that patients should contact a healthcare provider if the condition persists or recurs after completing the specified treatment regimen.

Q: Is Cotrisan safe to use for older adults?

A: Official information indicates that the medicine has not been studied specifically in older adults. However, based on the localized action of the drug, official information indicates that differences in safety or side effect profile are not anticipated.

Q: What are the most commonly reported side effects of Cotrisan?

A: The most commonly reported side effects are localized reactions that occur at the site of application. These reactions include irritation, a sensation of burning or stinging, and redness (erythema).

Q: Does Cotrisan cause any long-term side effects that people should know about?

A: Clinical trials and regulatory data primarily focus on short-term symptom patterns related to the length of the specified treatment. Due to this focus, a full profile of long-term effects after treatment discontinuation is not fully established in official documents.

Q: Is there a generic version of Cotrisan available?

A: Yes, the active ingredient in Cotrisan is Clotrimazole, which is widely available as an established generic medication. Clotrimazole is sold by various manufacturers in addition to several proprietary brand-name products.

Q: Do you need to take Cotrisan with food?

A: Regulatory documents for the various formulations do not contain specific instructions requiring the medicine to be taken with or without food for administration. Administration should follow the instructions specific to your dosage form.

Q: How quickly is Cotrisan absorbed by the body?

A: Systemic absorption is very limited, as the medicine is intended for localized delivery. Pharmacological data indicates that less than 0.5% is absorbed through intact skin, and between 3% and 10% is absorbed from the vaginal route.

Q: Why is the official name of Cotrisan different from its brand name?

A: The official name of the drug's active chemical compound is Clotrimazole, which is the generic name recognized internationally. Cotrisan is a specific registered trade name or brand name used by a manufacturer to market the medication.

Q: Can people with liver problems use Cotrisan?

A: For the oral lozenge formulation, official documents note that patients with pre-existing hepatic impairment (liver problems) should undergo periodic monitoring of their liver function tests. This precaution is related to documented occurrences of abnormal liver enzyme levels with this specific route of administration.

Q: Are there any specific warnings about Cotrisan and sun exposure?

A: Regulatory documents do not contain specific warnings or precautions regarding sun exposure or the risk of photosensitivity related to the use of this medicine. Use should align with the guidance provided in the official product information.

Q: What official warnings are attached to Cotrisan?

A: Official warnings state that the medicine is not to be used for ophthalmic purposes (eyes) and should be kept out of the eyes. It is also strictly contraindicated in individuals with known hypersensitivity or allergy to the active ingredient. Official documents describe the need to discontinue use if significant irritation or a lack of expected improvement is observed.

Q: Can I take other vitamins while on Cotrisan?

A: Regulatory sources note that certain vitamins have minor or unknown potential interactions with the active ingredient. However, official information notes that the localized application, resulting in limited systemic absorption, is a key factor in assessing the low risk of interaction.

Q: Is there a specific mechanism by which Cotrisan is eliminated from the body?

A: The small fraction of the active ingredient that is absorbed into the bloodstream is processed in the liver. It is then metabolized and eliminated from the body primarily through excretion in the bile.

How should Cotrisan be stored and disposed of?

How to Store and Dispose of Cotrisan

Official regulatory documents define strict requirements for the storage and disposal of Cotrisan to ensure product stability and public safety.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at a designated controlled room temperature, typically below 25°C (77°F).
Protection Keep the product in the original packaging, protected from light and moisture.
Handling Do not freeze. Keep the container tightly closed when not in use.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Cotrisan must not be disposed of in household trash or poured down a sink or toilet. The medicine should be returned to a pharmacy or an official drug take-back location. This process ensures proper handling and adherence to local environmental regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cotrisan found in:

A-Z Index: